HUMA vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 24, 2026

HUMA

47.9
AI Score
VS
CBIO Wins

CBIO

50.1
AI Score

Investment Advisor Scores

HUMA

48score
Recommendation
HOLD

CBIO

50score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HUMA CBIO Winner
Revenue 495,000 1.04M CBIO
Net Income -17.62M -23.28M HUMA
Net Margin -3559.4% -2240.9% CBIO
Operating Income -28.93M -24.73M CBIO
ROE -151.6% -12.7% CBIO
ROA -15.9% -11.7% CBIO
Total Assets 110.56M 199.13M CBIO
Cash 48.54M 189.16M CBIO
Current Ratio 3.93 13.78 CBIO
Free Cash Flow -25.28M -9.08M CBIO

Relative Price Performance (Last 90 Days)

HUMA 1M: -1.7% · 3M: -18.4% CBIO 1M: -13.5% · 3M: -18.2%

Current Technical Phase

HUMA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 47.4 · Price: $0.70

CBIO

Markdown
Sell / avoid

Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 41

RSI (14): 40.6 · Price: $14.78

Fundamentals Snapshot

Metric HUMA CBIO
Market Cap
Forward P/E -2.9 -5.7
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin -40.5% 1.0%
Operating Margin -57.0% -14.3%
EPS -0.63 -0.14
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, CBIO is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.